Literature DB >> 6188412

Progressive CT abnormalities despite clinical improvement in SSPE treated with inosiplex.

M J Noetzel, W E Dodson.   

Abstract

Inosiplex has been utilized in the treatment of subacute sclerosing panencephalitis (SSPE), though without unequivocally established beneficial effect. We report a patient whose computerized tomographic (CT) scans demonstrated the development of progressive cerebral atrophy and multifocal white matter lesions despite continuous treatment with inosiplex and periods of considerable clinical improvement or stabilization. The findings suggest that inosiplex may not have altered the pathological consequences of SSPE and that clinical staging categories alone may not be reliable long-term correlates of the progression of the disease. Controlled studies utilizing assessment of brain mass by CT scan or other imaging devices in addition to clinical staging are required to evaluate the efficacy of inosiplex.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6188412     DOI: 10.1002/ana.410130416

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  4 in total

1.  Intraventricular interferon in a case of subacute sclerosing panencephalitis.

Authors:  A Boiardi; S M Baldini; A Sghirlanzoni; R Mancuso; F Corridori
Journal:  Ital J Neurol Sci       Date:  1987-06

2.  Regional cerebral metabolic rate for glucose in subacute sclerosing panencephalitis.

Authors:  K Yanai; K Iinuma; K Tada; S Miyabayashi; H Fukuda; M Ito; T Matsuzawa
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

Review 3.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 4.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.